For the year ending 2025-12-31, RYTM has $480,196K in assets. $210,170K in debts. $54,301K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 54,301 | |||
| Short-term investments | 334,648 | |||
| Accounts receivable, net | 26,081 | |||
| Inventory | 25,753 | |||
| Prepaid expenses and other current assets | 26,133 | |||
| Total current assets | 466,916 | |||
| Property and equipment, net | 1,104 | |||
| Right-of-use asset | 3,049 | |||
| Intangible assets, net | 5,319 | |||
| Restricted cash | 522 | |||
| Other long-term assets | 3,286 | |||
| Total assets | 480,196 | |||
| Accounts payable | 13,947 | |||
| Accrued expenses and other current liabilities | 83,855 | |||
| Other current liability - lg chem | 0 | |||
| Deferred revenue | 194 | |||
| Deferred royalty obligation, current | 7,296 | |||
| Lease liability | 650 | |||
| Total current liabilities | 105,942 | |||
| Deferred royalty obligation | 100,886 | |||
| Lease liability, non-current | 3,342 | |||
| Derivative liability | 0 | |||
| Total liabilities | 210,170 | |||
| Series a convertible preferred stock, 0.001 par value 150,000 shares authorized 132,500 and 150,000 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively. liquidation preference of 132,500 and 150,000 as of december 31, 2025, and december 31, 2024, respectively | 130,957 | |||
| Common stock, 0.001 par value 120,000,000 shares authorized 67,205,321 and 62,390,654 shares issued and outstanding at december31, 2025 and december31, 2024, respectively | 67 | |||
| Additional paid-in capital | 1,491,675 | |||
| Accumulated other comprehensive (loss) income | -796 | |||
| Accumulated deficit | -1,351,877 | |||
| Total stockholders equity | 139,069 | |||
| Total liabilities, convertible preferred stock and stockholders equity | 480,196 | |||
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)